Menakuru, Sasmith R.Roepke, JanetSiddiqui, Salahuddin2024-01-102024-01-102023Menakuru SR, Roepke J, Siddiqui S. De-Novo B-Cell Prolymphocytic Leukemia. J Hematol. 2023;12(2):82-86. doi:10.14740/jh1096https://hdl.handle.net/1805/37939B-cell prolymphocytic leukemia (B-PLL) is a rare B-cell neoplasm that typically presents with splenomegaly, a rising white blood cell count, and may or may not have B symptoms. The diagnosis usually requires a bone marrow biopsy and aspirate with flow cytometry and cytogenetic studies. At least 55% of the lymphocytes in the peripheral blood must be prolymphocytes to be defined as B-PLL. A thorough differential diagnosis would include mantle cell lymphoma, chronic lymphocytic leukemia (CLL) with prolymphocytes, hairy cell leukemia, and splenic marginal zone lymphoma. B-PLL is managed with regimens utilized for CLL, such as ibrutinib and rituximab but is tailored for each individual. The authors report a rare case of B-PLL in a patient with no known history of CLL. The authors discuss this entity in context of the 2017 and 2022 World Health Organization (WHO) classifications, the latter of which no longer recognizes B-PLL as a distinct entity. The authors hope that this article helps practitioners with the diagnosis and treatment of B-PLL. Perhaps with better recognition, and better documentation of histopathologic features of these rare cases going forward, it may prove to be a distinct entity again in future classifications.en-USAttribution-NonCommercial 4.0 InternationalB-cell prolymphocytic leukemiaDifferential diagnosisTreatmentArticle